安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Rivus Pharmaceuticals
Rivus Pharmaceuticals, a leader in mitochondrial biology, is developing a new class of medicines to address a primary driver of cardio-metabolic disease: obesity
- Rivus Pharmaceuticals - LinkedIn
Rivus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on advancing cardiometabolic health The company’s lead candidate, HU6, is a potential best-in-class oral
- Rivus Pharmaceuticals 2026 Company Profile: Valuation, Funding . . .
Information on valuation, funding, cap tables, investors, and executives for Rivus Pharmaceuticals Use the PitchBook Platform to explore the full profile
- Rivus’ phase 2 obesity-related heart failure trial hits endpoint
Rivus Pharmaceuticals has plumped up the prospects of its fat-busting, muscle-sparing drug candidate, reporting a primary endpoint hit in a phase 2a trial of people with obesity-related heart
- Rivus Pharmaceuticals Expands Leadership Team and Establishes New San . . .
Rivus Pharmaceuticals, Inc , a leader in mitochondrial biology, is dedicated to improving metabolic health by advancing a new class of investigational therapies called Controlled Metabolic
- To penetrate crowded GLP-1 field, Rivus Pharma is taking a metabolic . . .
One of the potential new drug classes comes from biopharma Rivus Pharmaceuticals — these controlled metabolic accelerators are once-daily oral doses that stand out in clinical trials by being as effective as GLP-1s without some of the negative side effects, the company claims
- Rivus Pharmaceuticals Appoints Jorge Bartolome as Chief Executive Officer
Pharmaceutical veteran with extensive late-stage development and commercial experience to lead Rivus as it advances its pipeline of oral medicines that leverage energy expenditure for the
- Rivus Pharmaceuticals Announces Expansion of HU6 Clinical . . . - BioSpace
Rivus Pharmaceuticals, Inc , a leader in mitochondrial biology, is dedicated to improving metabolic health by advancing a new class of medicines called controlled metabolic accelerators (CMAs)
|
|
|